Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	JUN kinase activity	MAPK8 MAPK9 MAPK10	4.13e-08	3	70	3	GO:0004705
GeneOntologyMolecularFunction	protein serine/threonine/tyrosine kinase activity	MAPK8 MAPK9 MAPK10 MAP2K5	2.20e-05	47	70	4	GO:0004712
GeneOntologyMolecularFunction	MAP kinase activity	MAPK8 MAPK9 MAPK10	2.24e-05	16	70	3	GO:0004707
GeneOntologyMolecularFunction	ABC-type peptide transporter activity	ABCB9 TAP2	7.24e-05	4	70	2	GO:0015440
GeneOntologyMolecularFunction	galactosidase activity	GLA GLB1L2	2.52e-04	7	70	2	GO:0015925
GeneOntologyMolecularFunction	peptide transmembrane transporter activity	ABCB9 TAP2	4.29e-04	9	70	2	GO:1904680
GeneOntologyMolecularFunction	uniporter activity	MFSD1 SLC2A4	5.35e-04	10	70	2	GO:0015292
GeneOntologyMolecularFunction	glycine binding	GRIN1 GSS	1.07e-03	14	70	2	GO:0016594
GeneOntologyMolecularFunction	ATP-dependent activity	NLRP10 ABCB9 MYO10 STARD9 RNF213 ACSBG2 TAP2 DHX30	1.35e-03	614	70	8	GO:0140657
GeneOntologyMolecularFunction	oligopeptide transmembrane transporter activity	ABCB9 MFSD1	1.41e-03	16	70	2	GO:0035673
Domain	MAPK_JNK	MAPK8 MAPK9 MAPK10	5.46e-07	5	72	3	IPR008351
Domain	MAP_kinase_CS	MAPK8 MAPK9 MAPK10	1.18e-05	12	72	3	IPR003527
Domain	MAPK	MAPK8 MAPK9 MAPK10	1.18e-05	12	72	3	PS01351
Domain	ITI_HC_C	ITIH6 ITIH3	2.18e-04	6	72	2	IPR010600
Domain	ITI_HC_C	ITIH6 ITIH3	2.18e-04	6	72	2	PF06668
Domain	VIT	ITIH6 ITIH3	4.04e-04	8	72	2	PF08487
Domain	VIT	ITIH6 ITIH3	4.04e-04	8	72	2	SM00609
Domain	VIT	ITIH6 ITIH3	6.46e-04	10	72	2	PS51468
Domain	VIT	ITIH6 ITIH3	6.46e-04	10	72	2	IPR013694
Domain	dsrm	DHX30 STAU1	2.66e-03	20	72	2	PF00035
Domain	DS_RBD	DHX30 STAU1	2.94e-03	21	72	2	PS50137
Domain	FCH	SRGAP3 PACSIN2	3.22e-03	22	72	2	PF00611
Domain	FCH	SRGAP3 PACSIN2	3.22e-03	22	72	2	SM00055
Domain	FCH_dom	SRGAP3 PACSIN2	3.52e-03	23	72	2	IPR001060
Domain	ABC_membrane	ABCB9 TAP2	3.83e-03	24	72	2	PF00664
Domain	F_BAR	SRGAP3 PACSIN2	4.15e-03	25	72	2	IPR031160
Domain	F_BAR	SRGAP3 PACSIN2	4.15e-03	25	72	2	PS51741
Domain	ABC_TM1F	ABCB9 TAP2	5.19e-03	28	72	2	PS50929
Domain	ABC1_TM_dom	ABCB9 TAP2	5.19e-03	28	72	2	IPR011527
Pathway	KEGG_MEDICUS_PATHOGEN_HIV_VPR_TAT_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	5.90e-07	5	56	3	M47570
Pathway	KEGG_MEDICUS_ENV_FACTOR_PARAQUAT_TO_FAS_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	5.90e-07	5	56	3	M49021
Pathway	KEGG_MEDICUS_PATHOGEN_HTLV_1_TAX_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	5.90e-07	5	56	3	M49005
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	1.18e-06	6	56	3	M47680
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_IRE1A_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	1.18e-06	6	56	3	M47698
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_DJ1_TO_FAS_JNK_SIGNALING_PATWHAY	MAPK8 MAPK9 MAPK10	1.18e-06	6	56	3	M47712
Pathway	KEGG_MEDICUS_REFERENCE_IRE1A_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	2.06e-06	7	56	3	M47697
Pathway	KEGG_MEDICUS_REFERENCE_FAS_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	2.06e-06	7	56	3	M47711
Pathway	KEGG_MEDICUS_ENV_FACTOR_METALS_TO_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	3.28e-06	8	56	3	M47814
Pathway	REACTOME_ACTIVATION_OF_THE_AP_1_FAMILY_OF_TRANSCRIPTION_FACTORS	MAPK8 MAPK9 MAPK10	6.99e-06	10	56	3	MM15135
Pathway	REACTOME_ACTIVATION_OF_THE_AP_1_FAMILY_OF_TRANSCRIPTION_FACTORS	MAPK8 MAPK9 MAPK10	6.99e-06	10	56	3	M13962
Pathway	KEGG_MEDICUS_REFERENCE_MLK_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	1.27e-05	12	56	3	M47929
Pathway	KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	1.65e-05	13	56	3	M47594
Pathway	WP_BRAINDERIVED_NEUROTROPHIC_FACTOR_BDNF_SIGNALING	CRTC1 GRIN1 MAPK8 MAPK9 MAPK10 MAP2K5	2.18e-05	144	56	6	M39691
Pathway	KEGG_MEDICUS_REFERENCE_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	3.21e-05	16	56	3	M47569
Pathway	WP_TRANSLATION_INHIBITORS_IN_CHRONICALLY_ACTIVATED_PDGFRA_CELLS	MAPK8 MAPK9 MAPK10 MAP2K5	3.22e-05	46	56	4	M39805
Pathway	KEGG_TYPE_II_DIABETES_MELLITUS	MAPK8 MAPK9 MAPK10 SLC2A4	3.51e-05	47	56	4	M19708
Pathway	KEGG_MEDICUS_REFERENCE_IL1_IL1R_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	5.50e-05	19	56	3	M47471
Pathway	KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_PTP	MAPK8 MAPK9 MAPK10	6.45e-05	20	56	3	M47928
Pathway	REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1	MAPK8 MAPK9 MAPK10	8.67e-05	22	56	3	M859
Pathway	REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1	MAPK8 MAPK9 MAPK10	9.94e-05	23	56	3	MM15134
Pathway	KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10 SLC2A4	1.42e-04	67	56	4	M10462
Pathway	KEGG_MEDICUS_REFERENCE_TLR2_4_MAPK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	1.45e-04	26	56	3	M47565
Pathway	WP_ANGIOPOIETINLIKE_PROTEIN_8_REGULATORY_PATHWAY	MAPK8 MAPK9 MAPK10 MAP2K5 SLC2A4	1.74e-04	132	56	5	M39338
Pathway	WP_NANOPARTICLEMEDIATED_ACTIVATION_OF_RECEPTOR_SIGNALING	MAPK8 MAPK9 MAPK10	1.81e-04	28	56	3	M39572
Pathway	REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES	MAPK8 MAPK9 MAPK10	1.81e-04	28	56	3	MM15132
Pathway	WP_CHROMOSOMAL_AND_MICROSATELLITE_INSTABILITY_IN_COLORECTAL_CANCER	MAPK8 MAPK9 POLK MAPK10	1.98e-04	73	56	4	M39758
Pathway	WP_CANNABINOID_RECEPTOR_SIGNALING	MAPK8 MAPK9 MAPK10	2.02e-04	29	56	3	M39676
Pathway	KEGG_MEDICUS_PATHOGEN_KSHV_VGPCR_TO_GNB_G_PI3K_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	2.02e-04	29	56	3	M47466
Pathway	BIOCARTA_MAPK_PATHWAY	MAPK8 MAPK9 MAPK10 MAP2K5	2.32e-04	76	56	4	MM1433
Pathway	REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES	MAPK8 MAPK9 MAPK10	2.47e-04	31	56	3	M15195
Pathway	PID_NEPHRIN_NEPH1_PATHWAY	MAPK8 MAPK9 MAPK10	2.47e-04	31	56	3	M193
Pathway	PID_CD40_PATHWAY	MAPK8 MAPK9 MAPK10	2.47e-04	31	56	3	M45
Pathway	PID_WNT_NONCANONICAL_PATHWAY	MAPK8 MAPK9 MAPK10	2.71e-04	32	56	3	M23
Pathway	BIOCARTA_MAPK_PATHWAY	MAPK8 MAPK9 MAPK10 MAP2K5	2.96e-04	81	56	4	M13863
Pathway	REACTOME_GLYCOSPHINGOLIPID_CATABOLISM	GLA ASAH2 GLB1L2	3.26e-04	34	56	3	MM17076
Pathway	WP_13Q1212_COPY_NUMBER_VARIATION	SACS MAPK8 MAPK9	3.26e-04	34	56	3	M48103
Pathway	SIG_CD40PATHWAYMAP	MAPK8 MAPK9 MAPK10	3.26e-04	34	56	3	M12705
Pathway	WP_WNT_SIGNALING_IN_KIDNEY_DISEASE	MAPK8 MAPK9 MAPK10	3.86e-04	36	56	3	M39699
Pathway	WP_HOSTPATHOGEN_INTERACTION_OF_HUMAN_CORONAVIRUSES_MAPK_SIGNALING	MAPK8 MAPK9 MAPK10	3.86e-04	36	56	3	M39908
Pathway	REACTOME_OXIDATIVE_STRESS_INDUCED_SENESCENCE	MAPK8 MAPK9 MAPK10	4.19e-04	37	56	3	MM14899
Pathway	WP_INSULIN_SIGNALING	MAPK8 MAPK9 MAPK10 MAP2K5 SLC2A4	4.24e-04	160	56	5	MM15956
Pathway	WP_INSULIN_SIGNALING	MAPK8 MAPK9 MAPK10 MAP2K5 SLC2A4	4.24e-04	160	56	5	M39482
Pathway	WP_PANCREATIC_ADENOCARCINOMA_PATHWAY	MAPK8 MAPK9 POLK MAPK10	4.24e-04	89	56	4	M39732
Pathway	PID_FAS_PATHWAY	MAPK8 MAPK9 MAPK10	4.54e-04	38	56	3	M94
Pathway	REACTOME_GLYCOSPHINGOLIPID_CATABOLISM	GLA ASAH2 GLB1L2	4.90e-04	39	56	3	M48042
Pathway	PID_ERBB2_ERBB3_PATHWAY	MAPK8 MAPK9 MAPK10	7.01e-04	44	56	3	M175
Pathway	WP_WNT_SIGNALING_IN_KIDNEY_DISEASE	MAPK8 MAPK9 MAPK10	7.01e-04	44	56	3	MM15878
Pathway	BIOCARTA_EPONFKB_PATHWAY	ARNT GRIN1	8.33e-04	11	56	2	MM1393
Pathway	BIOCARTA_EPONFKB_PATHWAY	ARNT GRIN1	8.33e-04	11	56	2	M6917
Pathway	WP_MECHANOREGULATION_AND_PATHOLOGY_OF_YAPTAZ_VIA_HIPPO_AND_NONHIPPO_MECHANISMS	MAPK8 MAPK9 MAPK10	8.51e-04	47	56	3	M39829
Pathway	WP_INTERLEUKIN1_IL1_STRUCTURAL_PATHWAY	MAPK8 MAPK9 MAPK10	9.61e-04	49	56	3	M39543
Pathway	PID_FOXO_PATHWAY	MAPK8 MAPK9 MAPK10	9.61e-04	49	56	3	M136
Pathway	WP_5Q35_COPY_NUMBER_VARIATION	GRIN1 MAPK8 MAPK9 MAPK10	9.76e-04	111	56	4	M48089
Pathway	WP_CIRCADIAN_RHYTHM_GENES	ARNT CRTC1 MAPK8 MAPK9 MAPK10	1.19e-03	201	56	5	M39605
Pathway	REACTOME_GLYCOSPHINGOLIPID_METABOLISM	GLA ASAH2 GLB1L2	1.21e-03	53	56	3	MM14647
Pathway	REACTOME_CELLULAR_SENESCENCE	EHMT1 MAPK8 MAPK9 MAPK10	1.26e-03	119	56	4	MM14901
Pathway	WP_EFFECT_OF_OMEGA3_PUFA_ON_HUNTINGTONS_DISEASE_PATHWAYS	DHCR7 MAPK8 MAPK9 MAPK10	1.26e-03	119	56	4	M48309
Pathway	KEGG_NEUROTROPHIN_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10 MAP2K5	1.56e-03	126	56	4	M16763
Pathway	REACTOME_GLYCOSPHINGOLIPID_METABOLISM	GLA ASAH2 GLB1L2	1.57e-03	58	56	3	M576
Pathway	REACTOME_INTERLEUKIN_17_SIGNALING	MAPK8 MAPK9 MAPK10	1.65e-03	59	56	3	MM15128
Pathway	PID_PDGFRB_PATHWAY	PTPRJ MAPK8 MAPK9 MAPK10	1.70e-03	129	56	4	M186
Pathway	WP_NOVEL_INTRACELLULAR_COMPONENTS_OF_RIGILIKE_RECEPTOR_PATHWAY	MAPK8 MAPK9 MAPK10	1.73e-03	60	56	3	M39583
Pathway	REACTOME_FCERI_MEDIATED_MAPK_ACTIVATION	MAPK8 MAPK9 MAPK10	1.73e-03	60	56	3	MM14913
Pathway	KEGG_COLORECTAL_CANCER	MAPK8 MAPK9 MAPK10	1.90e-03	62	56	3	M14631
Pathway	KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	1.90e-03	62	56	3	M15569
Pathway	WP_CANONICAL_AND_NONCANONICAL_TGFB_SIGNALING	MAPK8 MAPK9	2.03e-03	17	56	2	M39686
Pathway	KEGG_INSULIN_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10 SLC2A4	2.12e-03	137	56	4	M18155
Pathway	KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION	MAPK8 MAPK9 MAPK10	2.48e-03	68	56	3	M16848
Pathway	PID_P75_NTR_PATHWAY	MAPK8 MAPK9 MAPK10	2.48e-03	68	56	3	M153
Pathway	KEGG_PANCREATIC_CANCER	MAPK8 MAPK9 MAPK10	2.69e-03	70	56	3	M9726
Pathway	REACTOME_INTERLEUKIN_17_SIGNALING	MAPK8 MAPK9 MAPK10	2.80e-03	71	56	3	M27382
Pathway	KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	2.80e-03	71	56	3	M15913
Pathway	BIOCARTA_INSULIN_PATHWAY	MAPK8 SLC2A4	3.10e-03	21	56	2	M765
Pathway	WP_TRANSCRIPTION_FACTOR_REGULATION_IN_ADIPOGENESIS	MAPK8 SLC2A4	3.40e-03	22	56	2	M39414
Pathway	WP_TYPE_II_DIABETES_MELLITUS	MAPK8 SLC2A4	3.40e-03	22	56	2	M39658
Pathway	WP_REGULATORY_CIRCUITS_OF_STAT3_SIGNALING	MAPK8 MAPK9 MAPK10	3.66e-03	78	56	3	M39824
Pathway	REACTOME_CELLULAR_RESPONSES_TO_STIMULI	ARNT EHMT1 NR3C2 MAPK8 MAPK9 MAPK10 NUP153	3.69e-03	505	56	7	MM15548
Pathway	WP_MAPK_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10 MAP2K5	3.71e-03	160	56	4	MM15990
Pathway	WP_ROLES_OF_CERAMIDES_IN_DEVELOPMENT_OF_INSULIN_RESISTANCE	MAPK8 SLC2A4	3.72e-03	23	56	2	M45533
Pathway	KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY	MAPK8 MAPK9 MAPK10	3.79e-03	79	56	3	M11816
Pathway	WP_MTHFR_DEFICIENCY	EHMT1 GRIN1	4.04e-03	24	56	2	M39755
Pathway	BIOCARTA_INSULIN_PATHWAY	MAPK8 SLC2A4	4.04e-03	24	56	2	MM1425
Pathway	PID_REG_GR_PATHWAY	MAPK8 MAPK9 MAPK10	4.21e-03	82	56	3	M115
Pubmed	Effects of SDF-1alpha and gp120IIIB on apoptotic pathways in SK-N-SH neuroblastoma cells.	GRIN1 MAPK8 MAPK9 MAPK10	6.16e-09	11	74	4	16481105
Pubmed	JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	30685843
Pubmed	JNK1 is required to preserve cardiac function in the early response to pressure overload.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	16579967
Pubmed	Specific pathophysiological functions of JNK isoforms in the brain.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	15673436
Pubmed	Activation of c-Jun N-terminal kinase mediates gp120IIIB- and nucleoside analogue-induced sensory neuron toxicity.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	15246824
Pubmed	Inhibition of c-Jun NH2-terminal kinase stimulates mu opioid receptor expression via p38 MAPK-mediated nuclear NF-κB activation in neuronal and non-neuronal cells.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	23485395
Pubmed	A critical role of neural-specific JNK3 for ischemic apoptosis.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	14657393
Pubmed	SAPKgamma/JNK1 and SAPKalpha/JNK2 mRNA transcripts are expressed in early gestation human placenta and mouse eggs, preimplantation embryos, and trophoblast stem cells.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	15474087
Pubmed	Disruption of JNK2 decreases the cytokine response to Plasmodium falciparum glycosylphosphatidylinositol in vitro and confers protection in a cerebral malaria model.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	17056565
Pubmed	The Roles of c-Jun N-Terminal Kinase (JNK) in Infectious Diseases.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	34502556
Pubmed	c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	14517246
Pubmed	Knockout of c-Jun N-terminal kinases 1, 2 or 3 isoforms induces behavioural changes.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	23428746
Pubmed	Hippocampal c-Jun-N-terminal kinases serve as negative regulators of associative learning.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	20926661
Pubmed	JNK3 is abundant in insulin-secreting cells and protects against cytokine-induced apoptosis.	MAPK8 MAPK9 MAPK10	9.25e-09	3	74	3	19609503
Pubmed	Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK).	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	15228592
Pubmed	JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis.	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	12818176
Pubmed	JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells.	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	20525557
Pubmed	c-JUN N-terminal kinase-1 (JNK1) but not JNK2 or JNK3 is involved in UV signal transduction in human epidermis.	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	16824735
Pubmed	Neuronal c-Jun is required for successful axonal regeneration, but the effects of phosphorylation of its N-terminus are moderate.	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	22372722
Pubmed	JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases.	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	9393873
Pubmed	Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein.	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	15693750
Pubmed	A novel Jun N-terminal kinase (JNK)-binding protein that enhances the activation of JNK by MEK kinase 1 and TGF-beta-activated kinase 1.	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	10471813
Pubmed	c-Jun N-terminal kinase 3 deficiency protects neurons from axotomy-induced death in vivo through mechanisms independent of c-Jun phosphorylation.	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	15528206
Pubmed	A selective small-molecule inhibitor of c-Jun N-terminal kinase 1.	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	19527717
Pubmed	APP upregulation contributes to retinal ganglion cell degeneration via JNK3.	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	29238071
Pubmed	Cortical interneurons require Jnk1 to enter and navigate the developing cerebral cortex.	MAPK8 MAPK9 MAPK10	3.69e-08	4	74	3	24899703
Pubmed	JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.	MAPK8 MAPK9 MAPK10	9.22e-08	5	74	3	14704277
Pubmed	The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development.	MAPK8 MAPK9 MAPK10	9.22e-08	5	74	3	10230788
Pubmed	The lectin jacalin induces phosphorylation of ERK and JNK in CD4+ T cells.	MAPK8 MAPK9 MAPK10	9.22e-08	5	74	3	12714584
Pubmed	Human immunodeficiency virus type 1 and its coat protein gp120 induce apoptosis and activate JNK and ERK mitogen-activated protein kinases in human neurons.	MAPK8 MAPK9 MAPK10	9.22e-08	5	74	3	9403476
Pubmed	Distinct roles of c-Jun N-terminal kinase isoforms in neurite initiation and elongation during axonal regeneration.	MAPK8 MAPK9 MAPK10	9.22e-08	5	74	3	20534829
Pubmed	JNK regulates the photic response of the mammalian circadian clock.	MAPK8 MAPK9 MAPK10	9.22e-08	5	74	3	22441692
Pubmed	gp160 of HIV or anti-CD4 monoclonal antibody ligation of CD4 induces inhibition of JNK and ERK-2 activities in human peripheral CD4+ T lymphocytes.	MAPK8 MAPK9 MAPK10	9.22e-08	5	74	3	9045910
Pubmed	JNK signaling is required for proper tangential migration and laminar allocation of cortical interneurons.	MAPK8 MAPK9 MAPK10	1.84e-07	6	74	3	31915148
Pubmed	HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism.	MAPK8 MAPK9 MAPK10	1.84e-07	6	74	3	19380828
Pubmed	HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling.	MAPK8 MAPK9 MAPK10	1.84e-07	6	74	3	11698270
Pubmed	NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer's disease.	MAPK8 MAPK9 MAPK10	1.84e-07	6	74	3	27076121
Pubmed	Neuroprotection by histone deacetylase-related protein.	MAPK8 MAPK9 MAPK10	1.84e-07	6	74	3	16611996
Pubmed	c-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer.	MAPK8 MAPK9 MAPK10	1.84e-07	6	74	3	19204086
Pubmed	A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab (SH3BP5), associates with mitochondria.	MAPK8 MAPK9 MAPK10	1.84e-07	6	74	3	12167088
Pubmed	JNK-mediated phosphorylation of DLK suppresses its ubiquitination to promote neuronal apoptosis.	MAPK8 MAPK9 MAPK10	3.22e-07	7	74	3	23979718
Pubmed	Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-JNK signaling pathway. A new mode of regulation of the MAP kinase cascade.	MAPK8 MAPK9 MAPK10	3.22e-07	7	74	3	12189133
Pubmed	Crosstalk of MAP3K1 and EGFR signaling mediates gene-environment interactions that block developmental tissue closure.	MAPK8 MAPK9 MAPK10	3.22e-07	7	74	3	38897570
Pubmed	Activation of mitogen activated protein kinases via complement receptor type 2.	MAPK8 MAPK9 MAPK10	3.22e-07	7	74	3	15603708
Pubmed	HIV-1 glycoprotein 120 induces the MMP-9 cytopathogenic factor production that is abolished by inhibition of the p38 mitogen-activated protein kinase signaling pathway.	MAPK8 MAPK9 MAPK10	3.22e-07	7	74	3	11468147
Pubmed	p38 MAPK signalling cascades: ancient roles and new functions.	MAPK8 MAPK9 MAPK10	3.22e-07	7	74	3	10878576
Pubmed	HIV-1 gp120 chemokine receptor-mediated signaling in human macrophages.	MAPK8 MAPK9 MAPK10	3.22e-07	7	74	3	12857973
Pubmed	Hyperphosphorylation of the retinoid X receptor alpha by activated c-Jun NH2-terminal kinases.	MAPK8 MAPK9 MAPK10	3.22e-07	7	74	3	10383391
Pubmed	Selective interaction of JNK protein kinase isoforms with transcription factors.	MAPK8 MAPK9 MAPK10	5.14e-07	8	74	3	8654373
Pubmed	Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.	ZNF462 ESYT2 DMXL2 DST SRGAP3 EHMT1 KAT6B	5.38e-07	225	74	7	12168954
Pubmed	JSAP1, a novel jun N-terminal protein kinase (JNK)-binding protein that functions as a Scaffold factor in the JNK signaling pathway.	MAPK8 MAPK9 MAPK10	7.70e-07	9	74	3	10523642
Pubmed	Suppression of ischemia in arterial occlusive disease by JNK-promoted native collateral artery development.	MAPK8 MAPK9 MAPK10	1.10e-06	10	74	3	27504807
Pubmed	IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition.	MAPK8 MAPK9 MAPK10	1.10e-06	10	74	3	11865055
Pubmed	Interaction of a mitogen-activated protein kinase signaling module with the neuronal protein JIP3.	MAPK8 MAPK9 MAPK10	1.10e-06	10	74	3	10629060
Pubmed	A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates.	MAPK8 MAPK9 MAPK10	1.10e-06	10	74	3	12788955
Pubmed	JNK initiates a cytokine cascade that causes Pax2 expression and closure of the optic fissure.	MAPK8 MAPK9 MAPK10	1.10e-06	10	74	3	12756228
Pubmed	The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis.	MAPK8 MAPK9 MAPK10	1.10e-06	10	74	3	15375216
Pubmed	Genetic interactions between Brca1 and Gadd45a in centrosome duplication, genetic stability, and neural tube closure.	MAPK8 MAPK9 MAPK10	1.51e-06	11	74	3	15123655
Pubmed	Phosphorylation of GSK-3beta by cGMP-dependent protein kinase II promotes hypertrophic differentiation of murine chondrocytes.	MAPK8 MAPK9 MAPK10	1.51e-06	11	74	3	18551195
Pubmed	Early construction of the thalamocortical axon pathway requires c-Jun N-terminal kinase signaling within the ventral forebrain.	MAPK8 MAPK9 MAPK10	1.51e-06	11	74	3	34494344
Pubmed	Wnt5a is a transcriptional target of Dlx homeogenes and promotes differentiation of interneuron progenitors in vitro and in vivo.	MAPK8 MAPK9 MAPK10	3.31e-06	14	74	3	21325536
Pubmed	Function of IRE1 alpha in the placenta is essential for placental development and embryonic viability.	MAPK8 MAPK9 MAPK10	3.31e-06	14	74	3	19805353
Pubmed	gp120-mediated induction of the MAPK cascade is dependent on the activation state of CD4(+) lymphocytes.	MAPK8 MAPK9 MAPK10	3.31e-06	14	74	3	12239168
Pubmed	HIV envelope gp120 activates human arterial smooth muscle cells.	MAPK8 MAPK9 MAPK10	4.13e-06	15	74	3	11504923
Pubmed	JNK-dependent Stat3 phosphorylation contributes to Akt activation in response to arsenic exposure.	MAPK8 MAPK9	4.47e-06	2	74	2	22696236
Pubmed	C-Jun N-terminal kinase (JNK) isoforms play differing roles in otitis media.	MAPK8 MAPK9	4.47e-06	2	74	2	25311344
Pubmed	Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo.	MAPK8 MAPK9	4.47e-06	2	74	2	16043490
Pubmed	Combined Activities of JNK1 and JNK2 in Hepatocytes Protect Against Toxic Liver Injury.	MAPK8 MAPK9	4.47e-06	2	74	2	26708719
Pubmed	Ablation of the spindle assembly checkpoint by a compound targeting Mps1.	MAPK8 MAPK9	4.47e-06	2	74	2	16113653
Pubmed	c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets.	MAPK8 MAPK9	4.47e-06	2	74	2	18853132
Pubmed	Ultrafine particles from diesel engines induce vascular oxidative stress via JNK activation.	MAPK8 MAPK9	4.47e-06	2	74	2	19154785
Pubmed	Role of the MAPK/cJun NH2-terminal kinase signaling pathway in starvation-induced autophagy.	MAPK8 MAPK9	4.47e-06	2	74	2	29950132
Pubmed	Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance.	MAPK8 MAPK9	4.47e-06	2	74	2	16818881
Pubmed	Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.	MAPK8 MAPK9	4.47e-06	2	74	2	23912840
Pubmed	Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1.	MAPK8 MAPK9	4.47e-06	2	74	2	12857751
Pubmed	JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis.	MAPK8 MAPK9	4.47e-06	2	74	2	21839715
Pubmed	JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.	MAPK8 MAPK9	4.47e-06	2	74	2	26235742
Pubmed	Prevention of steatosis by hepatic JNK1.	MAPK8 MAPK9	4.47e-06	2	74	2	19945406
Pubmed	C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma.	MAPK8 MAPK9	4.47e-06	2	74	2	12538493
Pubmed	Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling.	MAPK8 MAPK9	4.47e-06	2	74	2	19596001
Pubmed	Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma.	MAPK8 MAPK9	4.47e-06	2	74	2	17908987
Pubmed	c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists.	MAPK8 MAPK9	4.47e-06	2	74	2	19567513
Pubmed	Increased JNK in males compared with females in a rodent model of abdominal aortic aneurysm.	MAPK8 MAPK9	4.47e-06	2	74	2	22316675
Pubmed	Defective antiviral CD8 T-cell response and viral clearance in the absence of c-Jun N-terminal kinases.	MAPK8 MAPK9	4.47e-06	2	74	2	24673683
Pubmed	c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.	MAPK8 MAPK9	4.47e-06	2	74	2	11435459
Pubmed	[Sodium butyrate do not induce the program of premature senescence in transformants with JNK1,2 knockout].	MAPK8 MAPK9	4.47e-06	2	74	2	19140343
Pubmed	Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.	MAPK8 MAPK9	4.47e-06	2	74	2	23900581
Pubmed	Inhibition of c-Jun N-terminal kinase attenuates low shear stress-induced atherogenesis in apolipoprotein E-deficient mice.	MAPK8 MAPK9	4.47e-06	2	74	2	21629969
Pubmed	c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis.	MAPK8 MAPK9	4.47e-06	2	74	2	15572687
Pubmed	Identification and characterization of a TAP-family gene in the lamprey.	ABCB9 TAP2	4.47e-06	2	74	2	12679854
Pubmed	Hepatotoxicity mediated by pyrazole (cytochrome P450 2E1) plus tumor necrosis factor alpha treatment occurs in c-Jun N-terminal kinase 2-/- but not in c-Jun N-terminal kinase 1-/- mice.	MAPK8 MAPK9	4.47e-06	2	74	2	21748763
Pubmed	Purinergic (ATP) signaling stimulates JNK1 but not JNK2 MAPK in osteoblast-like cells: contribution of intracellular Ca2+ release, stress activated and L-voltage-dependent calcium influx, PKC and Src kinases.	MAPK8 MAPK9	4.47e-06	2	74	2	18625195
Pubmed	The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits.	MAPK8 MAPK9	4.47e-06	2	74	2	19620725
Pubmed	Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway.	MAPK8 MAPK9	4.47e-06	2	74	2	16571730
Pubmed	JNK inhibition reduces apoptosis and neovascularization in a murine model of age-related macular degeneration.	MAPK8 MAPK9	4.47e-06	2	74	2	23341606
Pubmed	c-Jun N-terminal kinase 2 promotes enterocyte survival and goblet cell differentiation in the inflamed intestine.	MAPK8 MAPK9	4.47e-06	2	74	2	28098247
Pubmed	Analysis of specialized DNA polymerases expression in human gliomas: association with prognostic significance.	POLL POLK	4.47e-06	2	74	2	20164241
Pubmed	c-Jun N-terminal kinase is upregulated in patients with hypospadias.	MAPK8 MAPK9	4.47e-06	2	74	2	23273084
Pubmed	An initial phase of JNK activation inhibits cell death early in the endoplasmic reticulum stress response.	MAPK8 MAPK9	4.47e-06	2	74	2	27122189
Pubmed	JNK2 up-regulates hypoxia-inducible factors and contributes to hypoxia-induced erythropoiesis and pulmonary hypertension.	MAPK8 MAPK9	4.47e-06	2	74	2	29118187
Interaction	SH3BP5 interactions	DST MAPK8 MAPK9 MAPK10	3.83e-06	30	72	4	int:SH3BP5
GeneFamily	Mitogen-activated protein kinases	MAPK8 MAPK9 MAPK10	5.93e-06	13	51	3	651
GeneFamily	ATP binding cassette subfamily B	ABCB9 TAP2	4.22e-04	11	51	2	806
GeneFamily	Armadillo repeat containing\|Protein phosphatase 1 regulatory subunits	SH2D4A SACS CSMD1 STAU1	1.68e-03	181	51	4	694
GeneFamily	DNA polymerases	POLL POLK	1.90e-03	23	51	2	535
GeneFamily	Rho GTPase activating proteins\|F-BAR domain containing	SRGAP3 PACSIN2	1.90e-03	23	51	2	1288
GeneFamily	DNAJ (HSP40) heat shock proteins\|C2 tensin-type domain containing	SACS DNAJC1	8.43e-03	49	51	2	584
CoexpressionAtlas	dev gonad_e13.5_F_SupCellPrec_Sry_top-relative-expression-ranked_1000	STUM SH2D4A DST SACS SRGAP3 STARD9 ASAH2 RNF213 GLB1L2 MAPK9 PACSIN2 ADGRA3	1.13e-05	804	70	12	gudmap_dev gonad_e13.5_F_SupCellPrec_Sry_1000
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	SOX5 NID2 MYO10 STARD9 CDH19	1.18e-05	178	74	5	185b44700f06ec58b3c09c80520502166c965fd6
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	SOX5 MYO10 STARD9 CDH19 SLC2A4	1.28e-05	181	74	5	451b87ac95154bb80018b8dd245b4a6389d81411
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	DST MYO10 SRGAP3 CNTN3 MAPK10	1.58e-05	189	74	5	203c80030df08ae112f9ae4043709f455d87ce89
ToppCell	nucseq-Mesenchymal-Myocytic-Myocytic_1-Pericyte\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SOX5 NID2 MYO10 STARD9 CDH19	1.62e-05	190	74	5	4eb92aef1ee868f4537483d19014d947b7684612
ToppCell	nucseq-Mesenchymal-Myocytic-Myocytic_1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SOX5 NID2 MYO10 STARD9 CDH19	1.62e-05	190	74	5	7be4341e2909101d756f14031c21e705eb45e69a
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Cortical_Collecting_Duct_Principal_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SOX5 MYO10 SRGAP3 NR3C2 MAPK10	1.62e-05	190	74	5	b7f8c2bb9459f1d7c1690069dd5a25a81a57cc84
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-2m-Neuronal-Intermediate\|2m / Sample Type, Dataset, Time_group, and Cell type.	SOX5 DST SRGAP3 MAPK8 KAT6B	2.07e-05	200	74	5	2a635694844ddabcd98462c5636a6f41a3f08a46
ToppCell	Control-B_intermediate-6\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	SOX5 PTPRJ CNTN3 TBC1D26	1.08e-04	148	74	4	662c057030effc9eb61216e81d3967e6983c244f
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Connecting_Tubule_Intercalated_Cell_Type_A\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SH2D4A PTPRJ SRGAP3 NR3C2	1.14e-04	150	74	4	87968ce885a4959616f0321f58517fe8029ba1b1
ToppCell	Control-Stromal-Pericyte\|Stromal / Disease state, Lineage and Cell class	CAPN14 MYO10 CDH19 SLC2A4	1.43e-04	159	74	4	6f50c381cd8a26a5a90bf0ce909713cea96910d7
ToppCell	343B-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	SH2D4A NR3C2 GLB1L2 TMEM231	1.57e-04	163	74	4	0ab043b68e8739adcedda01165a3758cd0d22728
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical-aged\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SOX5 NLRP10 STARD9 CNTN3	1.61e-04	164	74	4	f6a961fa2002da7d9679f32af99e1314c0593ef9
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Neuronal-Glial_immature-Glia_2_(ELN+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DST PTPRJ DNAJC1 CDH19	1.76e-04	168	74	4	af82e07d1eec51fc6530155f37addbce6221885d
ToppCell	Control\|World / group, cell type (main and fine annotations)	SOX5 NR3C2 MAPK10 PACSIN2	1.76e-04	168	74	4	a3511faf2cd2c2b9c8363c8b99da3f3609c43ed6
ToppCell	Control-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	STUM CSMD1 CDH19 ITIH3	1.88e-04	171	74	4	4ede831aed364cb5271f49a8b09bb6d0452f9b35
ToppCell	3'-GW_trimst-2-SmallIntestine-Neuronal-Glial_immature-Differentiating_glia\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DST DNAJC1 CDH19 TBC1D26	1.93e-04	172	74	4	bc3ed05fdd94d5e1f19285aea867b1453292baec
ToppCell	droplet-Fat-Bat-18m-Mesenchymal-nan\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NID2 APPL2 DNAJC1 CSMD1	2.06e-04	175	74	4	b4f01e7782cdd107d0817ef601891fd3a382bc35
ToppCell	droplet-Fat-Bat-18m-Mesenchymal-mesenchymal_stem_cell_of_adipose\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NID2 APPL2 DNAJC1 CSMD1	2.06e-04	175	74	4	ef6f811d8e1839f405c3b41090ddf79be57a099f
ToppCell	droplet-Fat-Bat-18m-Mesenchymal\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NID2 APPL2 DNAJC1 CSMD1	2.06e-04	175	74	4	7f7598d46d10bff1cbea42f950bdde1aaa16e9a4
ToppCell	10x3'2.3-week_17-19-Mesenchymal_osteo-stroma-chondrocyte\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	SOX5 SH2D4A ITIH6 CDH19	2.15e-04	177	74	4	915b848d789051a1c3bc6f6dc86955bb752276ab
ToppCell	droplet-Heart-nan-3m-Neuronal-cardiac_neuron\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SH2D4A SRGAP3 CSMD1 CDH19	2.29e-04	180	74	4	da723df348d7b8449bb1124f23fe6fa706412adb
ToppCell	droplet-Heart-nan-3m-Neuronal\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SH2D4A SRGAP3 CSMD1 CDH19	2.29e-04	180	74	4	5b146a94708b3c3610542a4d0925f3f7a2b19185
ToppCell	droplet-Heart-nan-3m-Neuronal-cardiac_neuron\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SH2D4A SRGAP3 CSMD1 CDH19	2.29e-04	180	74	4	50758b1e7be2e43f83c10ab106900c067e61f5f7
ToppCell	3'-GW_trimst-2-LargeIntestine-Neuronal-Glial_immature-Glia_1_(DHH+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NID2 DST DNAJC1 CDH19	2.29e-04	180	74	4	b294f9db1e2ff51c94cde64fae4c2b057c0030a1
ToppCell	NS-critical-d_0-4-Epithelial-Ionocyte\|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	ZNF462 SH2D4A DST DHCR7	2.34e-04	181	74	4	cfc3ed541d93158ce26641ea30b7573d93600a11
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	STUM SH2D4A PTPRJ MYO10	2.34e-04	181	74	4	30729f0364f719c044712a51453e22dc2c1a232b
ToppCell	3'-GW_trimst-2-SmallIntestine-Neuronal-Glial_immature-Glia_2_(ELN+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SOX5 DST DNAJC1 CDH19	2.34e-04	181	74	4	a436e7e4c36403257ea90160a58ca0d6d7c0cdfc
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Myeloid-Dendritic-conventional_dendritic_cell\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	DST MFSD1 DSE PACSIN2	2.39e-04	182	74	4	d57d18732aa6fb7b2d430601568f9ba525ac6e3c
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Myeloid-Dendritic\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	DST MFSD1 DSE PACSIN2	2.39e-04	182	74	4	9a68d3bd1cc9139de9e9e711c249d47ade826bb1
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Myeloid-Dendritic-conventional_dendritic_cell-DC_c2-CD1C\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	DST MFSD1 DSE PACSIN2	2.39e-04	182	74	4	c3fb1460160744144aa31afc76c0a4d42ebdeb91
ToppCell	Fetal_29-31_weeks-Mesenchymal-chondrocyte-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	SOX5 ITIH6 CDH19 ADGRA3	2.54e-04	185	74	4	8ed10ba581849c9c4ac4397226be2b62b4b3b900
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SH2D4A MYO10 SRGAP3 NR3C2	2.54e-04	185	74	4	3d73b3e0bceb192257e5cfbe64b7ccb379b6e22d
ToppCell	3'-GW_trimst-1-SmallIntestine-Neuronal-Glial_immature-Glia_1_(DHH+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SOX5 DST DNAJC1 CDH19	2.54e-04	185	74	4	dd17025d8c423aa0a451ac7f1f301c93528e0229
ToppCell	390C-Lymphocytic-CD4_T-cell-Treg_cell_1\|390C / Donor, Lineage, Cell class and subclass (all cells)	VPS13D SH2D4A MAP2K5 ZNF251	2.60e-04	186	74	4	064b6047215597465bb51a8a1547ef5a226552f9
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	STUM CSMD1 CDH19 ITIH3	2.60e-04	186	74	4	a95744b8649096bd7cfc3591a02841fa411085b3
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Cortical_Collecting_Duct_Intercalated_Cell_Type_A\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DST MYO10 ALPK3 NR3C2	2.60e-04	186	74	4	a6ef5d5944af5689b5f27bef89cd05645eedbe50
ToppCell	COPD-Stromal-Pericyte\|Stromal / Disease state, Lineage and Cell class	SOX5 MYO10 CDH19 SLC2A4	2.65e-04	187	74	4	406ecd1dabb3ed8d871aef159f7bd1e383434953
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Principal_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SOX5 SRGAP3 NR3C2 MAPK10	2.65e-04	187	74	4	f6217d0dd425eac76900b44a4e48f45475f3ac36
ToppCell	COVID-19-kidney-CD-IC-B\|kidney / Disease (COVID-19 only), tissue and cell type	SH2D4A SACS MYO10 NR3C2	2.65e-04	187	74	4	ce05b89860573fe0356102e2998d1ef6d1968034
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Outer_Medullary_Collecting_Duct_Principal_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SOX5 SRGAP3 NR3C2 MAPK10	2.65e-04	187	74	4	e3095455d2f255854f339f6b05fa87852af0700f
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DST MYO10 ALPK3 NR3C2	2.70e-04	188	74	4	e751cff2ac8fbc1487766c1871fcc5d1005286b0
ToppCell	390C-Lymphocytic-CD4_T-cell-Treg_cell_1\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	VPS13D SH2D4A MAP2K5 ZNF251	2.70e-04	188	74	4	b1ec7c45aedcc3d22cac898c6a3679e7f8b44c77
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	SOX5 MYO10 STARD9 CDH19	2.70e-04	188	74	4	ee151792c7ac9afe820f1a281c6dab383799f358
ToppCell	390C-Lymphocytic-CD4_T-cell-Treg_cell_1\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	VPS13D SH2D4A MAP2K5 ZNF251	2.70e-04	188	74	4	2c4e791df69a9df29922f9117e5cac7787c129ce
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	SOX5 SRGAP3 NR3C2 MAPK10	2.76e-04	189	74	4	c9565e962a13a7713056ec3dbb1b67d24f9889c7
ToppCell	Control-B_intermediate-6\|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5)	SOX5 PTPRJ SACS RNF213	2.76e-04	189	74	4	11cb9a16f1de8f60af2073ed7ea6d4f41c02f299
ToppCell	Mesenchymal-pericyte_cell\|World / Lineage, Cell type, age group and donor	SOX5 MYO10 STARD9 CDH19	2.76e-04	189	74	4	d7ed96add29f219183c802895fbff519b627f635
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SOX5 SRGAP3 NR3C2 MAPK10	2.76e-04	189	74	4	8ff3c3232eff9de4b5c9b22ecb82bc509d773f58
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SOX5 MYO10 SRGAP3 NR3C2	2.81e-04	190	74	4	11d3c31167ea71809b4cc3757a0c6ea54a448602
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Inner_Medullary_Collecting_Duct_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SOX5 PTPRJ SRGAP3 NR3C2	2.87e-04	191	74	4	3e828cffa24ded19f591a7ed6c1fe88ad57fdcac
ToppCell	P28-Mesenchymal-myocytic_cell-vascular_associated_smooth_muscle_cell\|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	STUM CSMD1 ITIH3 SLC2A4	2.93e-04	192	74	4	87c7780cf72f4c204f2a5f6655309d47a23c08ae
ToppCell	Epithelial\|World / Lineage, Cell type, age group and donor	SOX5 NR3C2 MAPK10 SCAI	2.93e-04	192	74	4	499e8893afea5e6d3371e0bd018f7e86a524d669
ToppCell	droplet-Heart-nan-18m-Mesenchymal-cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NLRP10 ALPK3 MAPK10 SLC2A4	2.93e-04	192	74	4	0bf99e029a06151092db1e8a0dcb45f4e688e771
ToppCell	Smart-start-Cell-Wel_seq-Neoplastic-Differentiated-like-AC-like-AC-like_Prolif-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SH2D4A GLB1L2 SFT2D3 ADGRA3	2.93e-04	192	74	4	d6f656be2698bd215717d35f4e7ab727c08c61e0
ToppCell	droplet-Heart-nan-18m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NLRP10 ALPK3 MAPK10 SLC2A4	2.93e-04	192	74	4	d766221acfce30cbf2c60b3ae40f6744968b952c
ToppCell	critical-Lymphoid-NK\|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	ZNF462 DST MYO10 CDH19	2.99e-04	193	74	4	6be11fef87af04ee7a3cc223882ccd4077caded9
ToppCell	COVID-19-kidney-CD-PC\|kidney / Disease (COVID-19 only), tissue and cell type	SOX5 SRGAP3 NR3C2 MAPK10	2.99e-04	193	74	4	738689d009e4b118d7ce3171a207294b95cbe78b
ToppCell	IPF-Stromal-Pericyte\|Stromal / Disease state, Lineage and Cell class	SOX5 MYO10 CDH19 SLC2A4	3.05e-04	194	74	4	3892b188f424ffb80f3c75a1b6709a21c1e1601d
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	SOX5 DST MYO10 SRGAP3	3.05e-04	194	74	4	b1bb0f846d2865efdd9bc8842b16b9d069785882
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	PTPRJ SRGAP3 MAPK10 ADGRA3	3.11e-04	195	74	4	6477e6e7be5bd8eb99119a12ae16334ccddecd43
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	SOX5 DST MYO10 SRGAP3	3.11e-04	195	74	4	0e55fa5b3cbeb7baee3d4ac272a3bf80381ec937
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	SOX5 PTPRJ NR3C2 MAPK10	3.17e-04	196	74	4	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	COVID-19-lung-Macrophage_LDB2hi_OSMRhi_YAP1hi\|COVID-19 / Disease (COVID-19 only), tissue and cell type	DMXL2 PTPRJ RNF213 MFSD1	3.23e-04	197	74	4	e42910a653a1b5bd90c090e9665a84871ed2873f
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	DST MYO10 SRGAP3 CNTN3	3.23e-04	197	74	4	0034bae02ee7fcfea520d453ca3c842ab6963b12
ToppCell	3'-GW_trimst-1-LargeIntestine-Neuronal-Glial_immature\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SOX5 DST DNAJC1 CDH19	3.29e-04	198	74	4	c8272ac4d90f2367f538f66db40de911ad73ea7f
ToppCell	COPD-Myeloid-Macrophage\|Myeloid / Disease state, Lineage and Cell class	ESYT2 DMXL2 CSMD1 MFSD1	3.35e-04	199	74	4	1cf1b2d6debf9e3389f1829dcaa2857e9533a080
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC-OPC-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ZNF462 DHCR7 CNTN3 CSMD1	3.35e-04	199	74	4	19a97e27a4758e794ce7246d295e112b47931a48
ToppCell	3'-GW_trimst-1-SmallIntestine-Neuronal-Glial_immature-ENCC/glia_Progenitor\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SOX5 DST DNAJC1 CDH19	3.35e-04	199	74	4	ce699726ac4825c65bf934cb9a76202ad7340596
ToppCell	3'-GW_trimst-1-LargeIntestine-Neuronal-Glial_immature-ENCC/glia_Progenitor\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SOX5 DST DNAJC1 CDH19	3.35e-04	199	74	4	8d13a9ea87f685b5a34b84c4571db6be753cf2d9
ToppCell	3'-GW_trimst-1-SmallIntestine-Neuronal-Glial_immature\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SOX5 DST DNAJC1 CDH19	3.35e-04	199	74	4	f1d5808ccb1d5d4e2d34f864e705e2484000e88f
ToppCell	Parenchymal-10x5prime-Immune_Myeloid-Macrophage_other-Macro_CHIT1\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	DMXL2 NTAN1 GLA MFSD1	3.35e-04	199	74	4	f987f48970aec46156b80656e49b9f3604f3758c
ToppCell	Tracheal-NucSeq-Stromal-Chondrocytic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ITIH6 CDH19 MAPK10 ADGRA3	3.42e-04	200	74	4	b5a54b9baf79aea01f76a161f0a39bbe87eb4945
ToppCell	Parenchyma_Control_(B.)-Stromal-TX-Smooth_muscle-1\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	SOX5 MYO10 STARD9 CDH19	3.42e-04	200	74	4	0c648941447c738caf62f2d71e296d6cca492c8b
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Smooth_muscle-1\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	SOX5 MYO10 STARD9 CDH19	3.42e-04	200	74	4	94f1fa61aa82eb9f411b2b1cb759476939ab5db7
ToppCell	Tracheal-NucSeq-Stromal-Chondrocytic-Chondrocyte\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ITIH6 CDH19 MAPK10 ADGRA3	3.42e-04	200	74	4	f5bd0b30e478dac09f68c46b0781f5f2e7e3c693
ToppCell	3'-GW_trimst-1-LargeIntestine-Neuronal\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DST DNAJC1 CDH19 MAPK10	3.42e-04	200	74	4	553e9612874480f4d2a45671462e266cd0a09321
ToppCell	LPS_IL1RA_TNF-Mesenchymal_myocytic-Pericyte-Pericyte_3\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	CSMD1 CDH19 ITIH3 SLC2A4	3.42e-04	200	74	4	c06426f877919bdd267ea2fd7e7973c6619832ae
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Smooth_muscle-1-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SOX5 MYO10 STARD9 CDH19	3.42e-04	200	74	4	522a51a284d2992d519c4669e1a48c8ebcc08c80
ToppCell	LPS_anti-TNF-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ESYT2 DST CNTN3 SLC2A4	3.42e-04	200	74	4	c596a53c0b63c9deaac7d99fcbdd94ecfa96b86c
Drug	benzothiazol-2-ylacetonitrile	MAPK8 MAPK9 MAPK10	2.91e-08	3	71	3	CID000342465
Drug	AC1MJ5N7	MAPK8 MAPK9 MAPK10	2.89e-07	5	71	3	CID003086135
Drug	AC1L3ZTY	MAPK8 MAPK9 MAPK10	1.01e-06	7	71	3	CID000098120
Drug	fludelone	MAPK8 MAPK9 MAPK10	1.01e-06	7	71	3	CID006918712
Drug	Ns102	MAPK8 MAPK9 MAPK10 MAP2K5	1.05e-06	25	71	4	CID005311098
Drug	idebenone	GRIN1 MAPK8 MAPK9 MAPK10 MAP2K5	1.12e-06	59	71	5	CID000003686
Drug	iclaprim	GLA NR3C2 MAPK8 MAPK9 MAPK10	1.44e-06	62	71	5	CID000213043
Drug	SDZ 62-434	MAPK9 KAT6B MAPK10	1.61e-06	8	71	3	CID000130786
Drug	methyldiazonium ion	MAPK8 MAPK9 MAPK10	1.61e-06	8	71	3	CID000115287
Drug	S 52	MAPK8 MAPK9 MAPK10	2.41e-06	9	71	3	CID000023681
Drug	AC1L6EKE	MAPK8 MAPK9 MAPK10	2.41e-06	9	71	3	CID000265720
Drug	K00039	MAPK8 MAPK9 MAPK10 MAP2K5	2.92e-06	32	71	4	CID009549277
Drug	D-JNKI-1	MAPK8 MAPK9 MAPK10	3.43e-06	10	71	3	ctd:C478085
Drug	irisolidone	MAPK8 MAPK9 MAPK10	3.43e-06	10	71	3	CID005281781
Drug	AC1NURR2	MAPK8 MAPK9 MAPK10	4.71e-06	11	71	3	CID005490351
Drug	9-CP-Ade	MAPK8 MAPK9 MAPK10	4.71e-06	11	71	3	CID000012852
Drug	pyridinyl imidazole	MAPK8 MAPK9 MAPK10 MAP2K5	4.74e-06	36	71	4	CID000005171
Drug	anthrapyrazole	MAPK8 MAPK9 MAPK10	6.27e-06	12	71	3	CID000119330
Drug	procymidone	MAPK8 MAPK9 POLK MAPK10	7.29e-06	40	71	4	CID000036242
Drug	Kinome_3024	MAPK9 MAPK10	9.59e-06	2	71	2	CID011539329
Drug	Kinome_3019	MAPK9 MAPK10	9.59e-06	2	71	2	CID011658882
Drug	Kinome_3025	MAPK9 MAPK10	9.59e-06	2	71	2	CID011715520
Drug	Kinome_3027	MAPK9 MAPK10	9.59e-06	2	71	2	CID011640926
Drug	Kinome_3028	MAPK9 MAPK10	9.59e-06	2	71	2	CID011590363
Drug	AC1MO44G	DST SRGAP3 MAPK8 MAPK9 MAPK10	1.02e-05	92	71	5	CID003363161
Drug	farnesylamine	MAPK8 MAPK9 MAPK10	1.03e-05	14	71	3	CID006449783
Drug	AC1L1B3Z	DST MAPK8 MAPK9 MAPK10	1.17e-05	45	71	4	CID000001273
Drug	phorone	MAPK8 MAPK9 MAPK10 GSS	1.17e-05	45	71	4	CID000010438
Drug	E-4IB	MAPK8 MAPK9 MAPK10	1.29e-05	15	71	3	CID000123372
Drug	Ambotz208527-57-5	MAPK8 MAPK9 MAPK10	1.92e-05	17	71	3	CID010258704
Drug	3-nonenal	MAPK8 MAPK9 MAPK10	2.29e-05	18	71	3	CID005283336
Drug	NSC363979	MAPK8 MAPK9 MAPK10	2.29e-05	18	71	3	CID000183413
Drug	Thr-Gly	MAPK8 MAPK9 MAPK10	2.72e-05	19	71	3	CID006427013
Drug	N-glyceryl-2-hexyl-3-keto-capramide	MAPK9 MAPK10	2.87e-05	3	71	2	CID011645877
Drug	CGC 11093	MAPK8 MAPK9	2.87e-05	3	71	2	ctd:C515676
Drug	Calebin-A	MAPK9 MAPK10	2.87e-05	3	71	2	CID000637429
Drug	Nitrofural [59-87-0]; Down 200; 20.2uM; HL60; HT_HG-U133A	VPS13D SH2D4A MYO10 CRTC1 MAPK10 TCTN2	3.11e-05	193	71	6	2459_DN
Drug	N,N-dimethyl-5H-purin-6-amine	MAPK8 MAPK9 MAPK10	3.19e-05	20	71	3	CID000436439
Drug	Morantel tartrate [26155-31-7]; Down 200; 10.8uM; HL60; HT_HG-U133A	FLII ARNT NTAN1 TRMT13 MAP2K5 DHX30	3.20e-05	194	71	6	1840_DN
Drug	AC1L1CFC	FLII MAPK8 MAPK9 MAPK10	3.24e-05	58	71	4	CID000001874
Drug	Econazole nitrate [24169-02-6]; Up 200; 9uM; HL60; HT_HG-U133A	ARNT EHMT1 POLL DNAJC1 MAPK8 MAPK10	3.30e-05	195	71	6	2396_UP
Drug	GSK-3 Inhibitor IX; Up 200; 0.5uM; PC3; HT_HG-U133A	NID2 ABCB9 ALPK3 POLL NR3C2 TCTN2	3.30e-05	195	71	6	7048_UP
Drug	Glipizide [29094-61-9]; Up 200; 9uM; MCF7; HT_HG-U133A	DMXL2 EHMT1 CRTC1 POLL KAT6B MAP2K5	3.39e-05	196	71	6	1508_UP
Drug	Metoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Up 200; 5.8uM; PC3; HT_HG-U133A	STUM ARNT ABCB9 ALPK3 CRTC1 GLB1L2	3.39e-05	196	71	6	4508_UP
Drug	Vigabatrin [60643-86-9]; Down 200; 31uM; HL60; HT_HG-U133A	SH2D4A EHMT1 POLL KAT6B MAPK10 TCTN2	3.49e-05	197	71	6	2452_DN
Drug	Phenacetin [62-44-2]; Down 200; 22.4uM; MCF7; HT_HG-U133A	FLII ABCB9 POLL GLB1L2 MAP2K5 TCTN2	3.59e-05	198	71	6	2832_DN
Drug	Arsenates	NID2 DNAJC1 MAPK8 MAPK9 MAPK10	3.99e-05	122	71	5	ctd:D001149
Drug	cyclosulfamuron	NR3C2 MAPK8 MAPK9 MAPK10	5.09e-05	65	71	4	CID006451137
Drug	1y2g	ARNT PTPRJ MAPK8 MAPK9 MAPK10	5.21e-05	129	71	5	CID005287936
Drug	octadec-9-en-1-amine	MAPK8 MAPK9 MAPK10	5.61e-05	24	71	3	CID000008219
Drug	GS-Hna	MAPK8 MAPK9 MAPK10	5.61e-05	24	71	3	CID000444455
Drug	JNK inhibitor VIII	MAPK9 MAPK10	5.73e-05	4	71	2	CID011624601
Drug	O(2)-(2,4-dinitrophenyl) 1-(4-(N,N-diethylcarboxamido)piperazin-1-yl)diazen-1-ium 1,2-diolate	MAPK8 MAPK9	5.73e-05	4	71	2	ctd:C495194
Drug	N1-Methyl-1,9-pyrazoloanthrone	MAPK9 MAPK10	5.73e-05	4	71	2	CID011665831
Drug	3-trifluoromethyl-4-nitrophenol	NR3C2 MAPK8 MAPK9 MAPK10	5.74e-05	67	71	4	CID000006931
Drug	2,4,3',5'-tetramethoxystilbene	MAPK8 MAPK9 MAPK10	6.36e-05	25	71	3	ctd:C440850
Drug	SR144528	MAPK8 MAPK9 MAPK10 DSE	6.81e-05	70	71	4	CID003081355
Drug	K00085	MAPK8 MAPK9 MAPK10	8.06e-05	27	71	3	CID009549283
Drug	AN-22	MAPK8 MAPK9 MAPK10	8.06e-05	27	71	3	CID000055769
Drug	AC1NDZBN	MAPK8 MAPK9 MAPK10	8.06e-05	27	71	3	CID004634037
Drug	SB225002	MAPK8 MAPK9 MAPK10	9.00e-05	28	71	3	CID003854666
Drug	DnHP	DST POLK	9.53e-05	5	71	2	CID000019284
Drug	AC1L9CMN	MAPK8 MAPK9	9.53e-05	5	71	2	CID000442339
Drug	betamethasone butyrate propionate	MAPK9 MAPK10	9.53e-05	5	71	2	CID000071470
Drug	ovatodiolide	MAPK8 MAPK9	9.53e-05	5	71	2	ctd:C432447
Drug	AC1NQZM2	MAPK8 MAPK9 MAPK10	1.00e-04	29	71	3	CID005282177
Drug	SB220025	MAPK8 MAPK9 MAPK10	1.00e-04	29	71	3	CID000005164
Drug	(2S)-2-amino-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-[[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]disulfanyl]propanoyl]-(carboxymethyl)amino]selanyl-(carboxymethyl)amino]-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid	MAPK8 MAPK9 MAPK10	1.23e-04	31	71	3	CID009543188
Drug	alpha-APP modulator	MAPK9 MAPK10	1.43e-04	6	71	2	CID009935767
Drug	Vinyl Compounds	MAPK8 MAPK9	1.43e-04	6	71	2	ctd:D014753
Drug	indole-5-carboxamide	MAPK8 MAPK9	1.43e-04	6	71	2	ctd:C514526
Drug	pramipexole	MAPK8 MAPK9	1.43e-04	6	71	2	ctd:C061333
Drug	Eosine I Bluish	MAPK8 MAPK9	1.43e-04	6	71	2	ctd:D010697
Drug	Sulfates	MAPK9 MAPK10 MAP2K5	1.48e-04	33	71	3	ctd:D013431
Drug	C11102	MAPK8 MAPK9 MAPK10 MAP2K5	1.52e-04	86	71	4	CID000443069
Drug	alpha-ketoisovalerate	MAPK8 MAPK9 KAT6B MAPK10	1.74e-04	89	71	4	CID000000049
Drug	9,12,15-octadecatrienoic acid	GLA EHMT1 MAPK8 MAPK9 MAPK10	1.76e-04	167	71	5	CID000000860
Drug	Dicumarol	MAPK8 MAPK9 MAPK10	1.77e-04	35	71	3	ctd:D001728
Drug	vioxanthin	MAPK9 MAPK10	1.99e-04	7	71	2	CID000119072
Drug	2-(4-((dimethylamino)methyl)benzylidene)-5,6-dimethoxy-2,3-dihydroinden-1-one	MAPK8 MAPK9	1.99e-04	7	71	2	ctd:C543150
Drug	satratoxin H	MAPK9 MAPK10	1.99e-04	7	71	2	CID000434380
Drug	iomeprol	MAPK8 MAPK9	1.99e-04	7	71	2	ctd:C057937
Drug	AA100	MAPK9 MAPK10	1.99e-04	7	71	2	CID010490261
Drug	SB366791	MAPK9 MAPK10	1.99e-04	7	71	2	CID000667594
Drug	LL Z1640-2	MAPK8 MAPK9	1.99e-04	7	71	2	ctd:C118715
Drug	poly(N-vinylpyrrolidine)	MAPK8 MAPK9	1.99e-04	7	71	2	ctd:C505150
Drug	amantadine	MAPK8 MAPK9 MAPK10 MAP2K5	2.23e-04	95	71	4	CID000002130
Drug	dihydroethidium	NR3C2 MAPK8 MAPK9 MAPK10	2.23e-04	95	71	4	CID000128682
Drug	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide	MAPK8 MAPK9 MAPK10	2.45e-04	39	71	3	ctd:C078131
Drug	hydroxytyrosol	MAPK8 MAPK9 MAPK10	2.45e-04	39	71	3	CID000082755
Drug	cystamine	NR3C2 MAPK8 MAPK9 MAPK10 PACSIN2	2.56e-04	181	71	5	CID000002915
Drug	p-XSC	MAPK8 MAPK9 MAPK10	2.64e-04	40	71	3	CID000005708
Drug	Silicates	MAPK8 MAPK9	2.65e-04	8	71	2	ctd:D017640
Drug	eupafolin	MAPK8 MAPK9	2.65e-04	8	71	2	ctd:C503624
Drug	I50 - 9	MAPK9 MAPK10	2.65e-04	8	71	2	CID000083651
Drug	caffeoylquinic acid	MAPK8 MAPK9	2.65e-04	8	71	2	ctd:C472707
Drug	tyrphostin A9	MAPK8 MAPK9	2.65e-04	8	71	2	ctd:C406122
Drug	desisobutyrylciclesonide	MAPK8 MAPK9	2.65e-04	8	71	2	ctd:C494355
Drug	aluminum chloride	GRIN1 MAPK8 MAPK9 GSS	2.93e-04	102	71	4	ctd:C010845
Drug	hydroxyflutamide	NR3C2 MAPK8 MAPK9 MAPK10	3.04e-04	103	71	4	CID000091649
Disease	Trigeminal Neuralgia	GRIN1 MAPK8 MAPK9	2.65e-06	12	69	3	C0040997
Disease	Secondary Trigeminal Neuralgia	GRIN1 MAPK8 MAPK9	2.65e-06	12	69	3	C0393787
Disease	Trigeminal Neuralgia, Idiopathic	GRIN1 MAPK8 MAPK9	2.65e-06	12	69	3	C0393786
Disease	age at menarche	ZNF462 SOX5 DST MYO10 CRTC1 KBTBD2 CSMD1 MAP2K5	7.31e-05	594	69	8	EFO_0004703
Disease	osteoarthritis biomarker measurement	CRTC1 CSMD1	8.03e-05	6	69	2	EFO_0005890
Disease	schizophrenia (implicated_via_orthology)	SRGAP3 GRIN1 CSMD1	5.50e-04	68	69	3	DOID:5419 (implicated_via_orthology)
Disease	Meckel-Gruber syndrome	TMEM231 TCTN2	5.55e-04	15	69	2	C0265215
Disease	pancreatic adenocarcinoma (is_implicated_in)	MAPK9 MAPK10	5.55e-04	15	69	2	DOID:4074 (is_implicated_in)
Disease	urate measurement, bone density	ATG9B SH2D4A CRTC1 NR3C2 MAPK8 KAT6B NUP153	6.05e-04	619	69	7	EFO_0003923, EFO_0004531
Disease	Intellectual Disability	ZNF462 SACS SRGAP3 DHCR7 L2HGDH GRIN1	6.26e-04	447	69	6	C3714756
Disease	Moyamoya Disease	GLA RNF213	7.16e-04	17	69	2	C0026654
Disease	Meckel syndrome type 1	TMEM231 TCTN2	8.05e-04	18	69	2	C3714506
Disease	facial asymmetry measurement	SOX5 MYO10	8.98e-04	19	69	2	EFO_0009751
Disease	Familial aplasia of the vermis	TMEM231 TCTN2	9.96e-04	20	69	2	cv:C0431399
Disease	Mechanical Allodynia	GRIN1 MAPK8 MAPK9	1.02e-03	84	69	3	C2936719
Disease	Allodynia	GRIN1 MAPK8 MAPK9	1.02e-03	84	69	3	C0458247
Disease	Hyperalgesia, Secondary	GRIN1 MAPK8 MAPK9	1.02e-03	84	69	3	C0751212
Disease	Hyperalgesia, Primary	GRIN1 MAPK8 MAPK9	1.02e-03	84	69	3	C0751211
Disease	Hyperalgesia, Thermal	GRIN1 MAPK8 MAPK9	1.02e-03	84	69	3	C0751214
Disease	Tactile Allodynia	GRIN1 MAPK8 MAPK9	1.02e-03	84	69	3	C0751213
Disease	Hyperalgesia	GRIN1 MAPK8 MAPK9	1.02e-03	84	69	3	C0020429
Disease	Nephritis, Tubulointerstitial	GLA DHCR7	1.10e-03	21	69	2	C0041349
Disease	eye color	SOX5 STUM CSMD1	1.24e-03	90	69	3	EFO_0003949
Disease	Nephritis, Interstitial	GLA DHCR7	1.44e-03	24	69	2	C0027707
Disease	cerebellum cortex volume change measurement, age at assessment	CRTC1 CSMD1	1.69e-03	26	69	2	EFO_0008007, EFO_0021497
Disease	type 2 diabetes mellitus (implicated_via_orthology)	MAPK8 MAPK9 SLC2A4	1.93e-03	105	69	3	DOID:9352 (implicated_via_orthology)
Disease	neuroticism measurement, cognitive function measurement	SOX5 NR3C2 CSMD1 CDH19 SCAI STAU1	2.09e-03	566	69	6	EFO_0007660, EFO_0008354
Disease	Epileptic encephalopathy	GRIN1 MAPK10	2.25e-03	30	69	2	C0543888
Disease	Familial aplasia of the vermis	TMEM231 TCTN2	2.25e-03	30	69	2	C0431399

Protein segments in the cluster

Peptide	Gene	Start	Entry
PLVYKAIQQGINAVN	ACSBG2	601	Q5FVE4
VATVGYQPQELLGKN	ARNT	381	P27540
DVGQQPLRINGVKVY	ESYT2	241	A0FGR8
LSVYDGQPQQGNLKV	CSMD1	86	Q96PZ7
YGLNLAIQNGPIKSN	ADGRA3	1281	Q8IWK6
LVYVLGQQPLARQGE	ALPK3	6	Q96L96
VIAINQDPLGKQGYQ	GLA	316	P06280
QDPLGKQGYQLRQGD	GLA	321	P06280
LQYAPKQQLLISGGR	DMXL2	2906	Q8TDJ6
AGLYPNLIQVRQGKV	DHX30	1021	Q7L2E3
PAGVVNKYQINGLQA	DHCR7	136	Q9UBM7
RQQQAAPNLRKLIYG	BMS1	681	Q14692
QQKLLELALQQYPRG	DNAJC1	501	Q96KC8
QNLTQDGKGIYLQKP	CAPN14	661	A8MX76
ENGQQQKYLGVCRLP	POLL	466	Q9UGP5
NNGRLLKDGPQYRVN	KAT6B	161	Q8WYB5
YQQLKPIGSGAQGIV	MAPK9	26	P45984
QVNISGLKPGVQYNI	PTPRJ	256	Q12913
NPIIYGLRNNEVKGA	OR10A7	286	Q8NGE5
KAVQGAQQPSLYQIR	FLII	1046	Q13045
NGVTGQLNIVQYIKP	NR3C2	386	P08235
LKRYQNLKPIGSGAQ	MAPK10	61	P53779
IPRLQALYEKGLQNG	L2HGDH	146	Q9H9P8
QQKPGQAPRLLIYGA	IGKV3D-7	61	A0A0C4DH55
GVNGRYNQVLLVAKP	NLRP10	116	Q86W26
LQFGYNIGVINAPQK	SLC2A4	36	P14672
NISLPGEQYGQKSLN	DST	2286	Q03001
NKGNVDGVQINRSPY	ASAH2	246	Q9NR71
LGRFPYPQIQKNQGS	MAP2K5	351	Q13163
YQNLKPIGSGAQGIV	MAPK8	26	P45983
NDIYIAGGQVPLKNT	KBTBD2	316	Q8IY47
QKGNIQGGRIVDYLL	MYO10	231	Q9HD67
GVGAYNPQLNLKNVQ	DSE	541	Q9UL01
VLLYLVNRAQGGNLN	MFSD1	436	Q9H3U5
QQIGYLPLNGTRLQK	NID2	1116	Q14112
KGRLDNGQVGLYPAN	PACSIN2	466	Q9UNF0
ARLQLQKSQYLQLGP	CRTC1	41	Q6UUV9
PQINRNLIQKAGYLN	APPL2	271	Q8NEU8
NYQVALANKGLLPAR	ATG9B	366	Q674R7
QGQYQLVVSLRPGQL	ITIH6	156	Q6UXX5
QYKRGGPIIAVQVEN	GLB1L2	186	Q8IW92
FVLKPQREGGGNNLY	GSS	361	P48637
RYPEGGQILKELIQN	SACS	106	Q9NZJ4
GSNGYILNKPALQAQ	EHMT1	121	Q9H9B1
GNNARLLYSLLQGQP	CDH19	181	Q9H159
RYKLNGGNLVVINPN	CNTN3	76	Q9P232
DQGRIQYLQQKGFSP	TRMT13	436	Q9NUP7
LPGIVGLNNIKANDY	USP39	221	Q53GS9
NVRNAIGGKFPLYNL	ITIH3	411	Q06033
ARVNIQKYVPGLQTQ	GUCY1B2	211	O75343
RQLQEYLAQGKAGGP	SFT2D3	6	Q587I9
LQNLYQPTGGQVLLD	TAP2	516	Q03519
PAQGQGNIIITKYEQ	TBC1D26	11	Q86UD7
GAYLKNNLPVLLQNQ	STARD9	1791	Q9P2P6
VGPQGLLYVQQRELA	NTAN1	41	Q96AB6
QVEALYRLQGQKEPG	MRPS2	266	Q9Y399
NAPRQPLYNIQVRKG	SPATA9	116	Q9BWV2
QLLAQGGLYAKLVQR	ABCB9	726	Q9NP78
RNQLAGVKQQLYHPA	TEPP	86	Q6URK8
NQRGIYVIQAPKGGQ	RNF213	1541	Q63HN8
KVQYNGRPLFVAGGQ	nan	246	Q6ZTK2
YGQGINPISRLAQIQ	STAU1	281	O95793
NLYGLQQQGIFRVPG	SRGAP3	531	O43295
LAISQGYKEQGIPQQ	STUM	126	Q69YW2
QILGQGPKLLIQFQN	TRBV11-2	56	A0A584
KNKPNGQYQILPNRQ	POLK	326	Q9UBT6
QLFNGLRDLPQYGQK	SCAI	71	Q8N9R8
NSGAYPQKPLRNQGV	SH2D4A	296	Q9H788
IKPYQQGRQQHQGIL	NUP153	26	P49790
QAEGRQLGPQQRALY	ZNF251	26	Q9BRH9
PGSQLYVNGDLRLQQ	TMEM231	166	Q9H6L2
LGNGPRLQNSTYQCK	ZNF462	1881	Q96JM2
PAQGQGNIIITKYEQ	TBC1D28	11	Q2M2D7
PGLGPLQLQQLYAAQ	SOX5	331	P35711
NPGYQLGKPVRALNI	TCTN2	436	Q96GX1
KVIQQGNRPGLIYNI	VPS13D	3366	Q5THJ4
LQNRKLVQVGIYNGT	GRIN1	356	Q05586